HOME >> BIOLOGY >> NEWS
Dana-Farber researchers to lead collaborative smallpox studies

BOSTONThe National Institute of Allergy and Infectious Diseases (NIAID) announced today that it has selected Dana-Farber Cancer Institute to head one of five newly established Cooperative Centers for Translational Research on Human Immunology and Biodefense.

Investigators at Dana-Farber and their colleagues from other Harvard Medical School-affiliated hospitals and the University of Massachusetts Medical School will receive a $15.1 million grant over 4 1/2 years to fund research on a safer vaccine against the smallpox virus, an agent that has raised concerns as a potential bioterror weapon.

NIAID is committing approximately $85 million to develop the Cooperative Centers, a biodefense research network that focuses on the immune system. Investigators from the Cooperative Centers will work closely on projects to improve the nation's ability to respond to a biological terror attack. The goal of the research is to develop a better understanding of how the human immune system responds to disease-causing organisms, whether they are deliberately released or naturally occurring.

The Dana-Farber grant will support studies probing the body's immune response to the virus used in the current smallpox vaccine and to other viruses that may offer safer alternatives. The current vaccine, which is credited with eradicating smallpox around the world but hasn't been in general use in the United States since the early 1970s, uses a vaccinia virus a cousin of the smallpox virus to prompt an immune response that protects against smallpox. Though effective, the vaccine can cause serious complications in people with weakened immune systems, such as cancer and AIDS patients, or with skin diseases such as eczema.

"The aim of our research is to understand, in precise detail, the nature of the human immune system's response to the vaccinia virus and to other related viruses that potentially could be used as vaccines," says Dana-Farber's Ellis Reinherz, M.D., w
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
17-Sep-2003


Page: 1 2

Related biology news :

1. Kinase backgrounder: Iressa discovery part of major kinase project at Dana-Farber
2. Dana-Farber launches Center for Applied Cancer Science
3. Dana-Farber scientists discover natural blocker of HIV-1 virus
4. Dana-Farber launches NFCR Center for Therapeutic Antibody Research and Engineering
5. Belgian researchers explore revolutionary approach to angiogenesis
6. Award winning researchers reveal potential new role for Glivec
7. $7.5 Million grant to Yale researchers for role of viruses in cancer
8. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
9. Joslin researchers clarify mechanisms for beta-cell formation
10. Virginia Tech researchers to release findings on Smith River Project
11. Molecular motor myosin VI moves hand over hand, researchers say

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/11/2020)... ... June 08, 2020 , ... Cryo-Cell ... protective measures to protect workers in the medical field. The face masks will ... valiantly risk their lives every day to provide healthcare to pregnant women. The ...
(Date:6/5/2020)... MURRIETA, Calif. (PRWEB) , ... June 04, 2020 , ... ... , has filed a new patent application for simplified sample preparation for Next ... technology that will greatly reduce cost, time, and complexity of sample preparation. , “I ...
(Date:6/5/2020)... , ... June 04, 2020 , ... Greffex, a pioneering ... its Board of Directors. , “Neil understands the need for a global perspective to ... and CEO of Greffex. Mr. Bush will serve as an independent, director of the ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... 22, 2020 , ... Dracen Pharmaceuticals Inc., announced today that ... during the American Association for Cancer Research Virtual meeting. One poster describes the ... single agent activity in KEAP1 mutant tumor models of NSCLC. , ...
(Date:6/11/2020)... ... June 08, 2020 , ... Greffex, a leading ... use of proprietary clean viral vectors, recently announced a key manufacturing agreement with ... platform is the world’s most successful gene therapy delivery vehicle (vector) with broad ...
(Date:6/11/2020)... ... ... Reducing carbon emissions has been and will continue to be a major ... ways to reduce CO2 is something we can’t avoid. , To protect the ... produced today are created from recycled cooking oil or crops. Unfortunately, these sources are ...
(Date:5/30/2020)... ... May 29, 2020 , ... Medrio, Inc., ... animal health markets, has enabled Cytovale, Inc., a medical technology company dedicated to ... to achieve their first patient in (FPI) in just seven days. The Cytovale ...
Breaking Biology Technology:
Cached News: